semaglutide being pulled from market Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Semaglutide and Tirzepatide off FDA

Each vial features a secure QR code for instant access to batch-specific HPLC/MS documentation to verify 99%+ purity

Glycosaminoglycan and proteoglycan biosynthesis pathway investigation

The FDA warns taking high doses of the anti-diarrhea medication Imodium may lead to serious and potentially fatal heart problems

Roches oral GLP-1 receptor agonist CT-996obtained in the $2.7 billion acquisition of Carmot Therapeuticsreduced body weight by more than 6% at four weeks versus placebo in a Phase I trial.

The phase 3 TRANSCEND-T2D-1 trial evaluated the triple GIP, GLP-1, and glucagon receptor agonist in adults with type 2 diabetes inadequately controlled with diet and exercise alone.

Perhaps, we will be able to help some people to avoid side effects with one medicine by using a different one, or by using lower doses with specific combinations